Literature DB >> 20073015

Use of genetically modified muscle and fat grafts to repair defects in bone and cartilage.

C H Evans1, F-J Liu, V Glatt, J A Hoyland, C Kirker-Head, A Walsh, O Betz, J W Wells, V Betz, R M Porter, F A Saad, L C Gerstenfeld, T A Einhorn, M B Harris, M S Vrahas.   

Abstract

We report a novel technology for the rapid healing of large osseous and chondral defects, based upon the genetic modification of autologous skeletal muscle and fat grafts. These tissues were selected because they not only possess mesenchymal progenitor cells and scaffolding properties, but also can be biopsied, genetically modified and returned to the patient in a single operative session. First generation adenovirus vector carrying cDNA encoding human bone morphogenetic protein-2 (Ad.BMP-2) was used for gene transfer to biopsies of muscle and fat. To assess bone healing, the genetically modified ("gene activated") tissues were implanted into 5mm-long critical size, mid-diaphyseal, stabilized defects in the femora of Fischer rats. Unlike control defects, those receiving gene-activated muscle underwent rapid healing, with evidence of radiologic bridging as early as 10 days after implantation and restoration of full mechanical strength by 8 weeks. Histologic analysis suggests that the grafts rapidly differentiated into cartilage, followed by efficient endochondral ossification. Fluorescence in situ hybridization detection of Y-chromosomes following the transfer of male donor muscle into female rats demonstrated that at least some of the osteoblasts of the healed bone were derived from donor muscle. Gene activated fat also healed critical sized defects, but less quickly than muscle and with more variability. Anti-adenovirus antibodies were not detected. Pilot studies in a rabbit osteochondral defect model demonstrated the promise of this technology for healing cartilage defects. Further development of these methods should provide ways to heal bone and cartilage more expeditiously, and at lower cost, than is presently possible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20073015      PMCID: PMC4382019          DOI: 10.22203/ecm.v018a09

Source DB:  PubMed          Journal:  Eur Cell Mater        ISSN: 1473-2262            Impact factor:   3.942


  40 in total

Review 1.  The 2003 Nicolas Andry Award. Orthopaedic gene therapy.

Authors:  Christopher H Evans; Steven C Ghivizzani; Paul D Robbins
Journal:  Clin Orthop Relat Res       Date:  2004-12       Impact factor: 4.176

2.  Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene.

Authors:  A W Baltzer; C Lattermann; J D Whalen; P Wooley; K Weiss; M Grimm; S C Ghivizzani; P D Robbins; C H Evans
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

3.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

4.  Expression of VEGF121 and VEGF165 in hypertrophic chondrocytes of the human growth plate and epiphyseal cartilage.

Authors:  Wolf Petersen; Michael Tsokos; Thomas Pufe
Journal:  J Anat       Date:  2002-08       Impact factor: 2.610

5.  Age-dependent expression of VEGF isoforms and receptors in the rabbit anterior cruciate ligament.

Authors:  Jochen G Hofstaetter; Fawzy A Saad; Ilse-Gerlinde Sunk; Klaus Bobacz; Ingeborg Friehs; Melvin J Glimcher
Journal:  Biochim Biophys Acta       Date:  2007-02-27

6.  The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats.

Authors:  A W Yasko; J M Lane; E J Fellinger; V Rosen; J M Wozney; E A Wang
Journal:  J Bone Joint Surg Am       Date:  1992-06       Impact factor: 5.284

7.  Healing of segmental bone defects by direct percutaneous gene delivery: effect of vector dose.

Authors:  Volker M Betz; Oliver B Betz; Vaida Glatt; Louis C Gerstenfeld; Thomas A Einhorn; Mary L Bouxsein; Mark S Vrahas; Christopher H Evans
Journal:  Hum Gene Ther       Date:  2007-10       Impact factor: 5.695

8.  Gene delivery to cartilage defects using coagulated bone marrow aspirate.

Authors:  A Pascher; G D Palmer; A Steinert; T Oligino; E Gouze; J-N Gouze; O Betz; M Spector; P D Robbins; C H Evans; S C Ghivizzani
Journal:  Gene Ther       Date:  2004-01       Impact factor: 5.250

9.  Heterotopic ossification in high-energy wartime extremity injuries: prevalence and risk factors.

Authors:  Jonathan Agner Forsberg; Joseph M Pepek; Scott Wagner; Kevin Wilson; James Flint; Romney C Andersen; Doug Tadaki; Frederick A Gage; Alexander Stojadinovic; Eric A Elster
Journal:  J Bone Joint Surg Am       Date:  2009-05       Impact factor: 5.284

Review 10.  Fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Martine Le Merrer; David L Glaser; Robert J Pignolo; Robert E Goldsby; Joseph A Kitterman; Jay Groppe; Eileen M Shore
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

View more
  44 in total

1.  Determination of effective rAAV-mediated gene transfer conditions to support chondrogenic differentiation processes in human primary bone marrow aspirates.

Authors:  A Rey-Rico; J Frisch; J K Venkatesan; G Schmitt; H Madry; M Cucchiarini
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

2.  Ex vivo regional gene therapy with human adipose-derived stem cells for bone repair.

Authors:  Venus Vakhshori; Sofia Bougioukli; Osamu Sugiyama; Hyunwoo P Kang; Amy H Tang; Sang-Hyun Park; Jay R Lieberman
Journal:  Bone       Date:  2020-07-02       Impact factor: 4.398

3.  Post implantation fate of adipogenic induced mesenchymal stem cells on Type I collagen scaffold in a rat model.

Authors:  Balu Venugopal; Francis B Fernandez; V S Harikrishnan; Annie John
Journal:  J Mater Sci Mater Med       Date:  2017-01-20       Impact factor: 3.896

Review 4.  Gene therapy for the regeneration of bone.

Authors:  Christopher Evans
Journal:  Injury       Date:  2011-04-13       Impact factor: 2.586

5.  Evaluation of BMP-2 gene-activated muscle grafts for cranial defect repair.

Authors:  Fangjun Liu; Ryan M Porter; James Wells; Vaida Glatt; Carmencita Pilapil; Christopher H Evans
Journal:  J Orthop Res       Date:  2011-12-28       Impact factor: 3.494

6.  "Same day" ex-vivo regional gene therapy: a novel strategy to enhance bone repair.

Authors:  Mandeep S Virk; Osamu Sugiyama; Sang H Park; Sanjiv S Gambhir; Douglas J Adams; Hicham Drissi; Jay R Lieberman
Journal:  Mol Ther       Date:  2011-02-22       Impact factor: 11.454

Review 7.  Gene therapy for chondral and osteochondral regeneration: is the future now?

Authors:  Daniele Bellavia; F Veronesi; V Carina; V Costa; L Raimondi; A De Luca; R Alessandro; M Fini; G Giavaresi
Journal:  Cell Mol Life Sci       Date:  2017-09-01       Impact factor: 9.261

8.  Rapid and reliable healing of critical size bone defects with genetically modified sheep muscle.

Authors:  F Liu; E Ferreira; R M Porter; V Glatt; M Schinhan; Z Shen; M A Randolph; C A Kirker-Head; C Wehling; M S Vrahas; C H Evans; J W Wells
Journal:  Eur Cell Mater       Date:  2015-09-21       Impact factor: 3.942

9.  Enhancement of BMP-2 induced bone regeneration by SDF-1α mediated stem cell recruitment.

Authors:  Stefan Zwingenberger; Zhenyu Yao; Angela Jacobi; Corina Vater; Roberto D Valladares; Chenguang Li; Christophe Nich; Allison J Rao; Jane E Christman; Joseph K Antonios; Emmanuel Gibon; Axel Schambach; Tobias Maetzig; Stuart B Goodman; Maik Stiehler
Journal:  Tissue Eng Part A       Date:  2013-11-12       Impact factor: 3.845

10.  Muscle cell-derived factors inhibit inflammatory stimuli-induced damage in hMSC-derived chondrocytes.

Authors:  R S Rainbow; H Kwon; A T Foote; R C Preda; D L Kaplan; L Zeng
Journal:  Osteoarthritis Cartilage       Date:  2013-04-20       Impact factor: 6.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.